Apr 26, 2023
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
Apr 16, 2023
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Apr 11, 2023
Immutep Announces Changes to the Board
Mar 31, 2023
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
